Literature DB >> 16931824

Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania.

Fabrizio Tediosi1, Guy Hutton, Nicolas Maire, Thomas A Smith, Amanda Ross, Marcel Tanner.   

Abstract

We model the cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the Expanded Program on Immunization. We use a dynamic stochastic simulation model of the epidemiology of Plasmodium falciparum in malaria-endemic areas and of case management in Tanzania. We consider a range of vaccine characteristics and a range of transmission settings. At low vaccine prices, the cost-effectiveness of such vaccines may be similar to that of other established preventative and curative interventions against malaria. The cost-effectiveness ratio increases rapidly and approximately linearly with vaccine cost per dose. The approach can be adopted for comparative analyses of the cost effectiveness of different vaccines and other intervention strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931824     DOI: 10.4269/ajtmh.2006.75.131

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

1.  Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios.

Authors:  Paul E Parham; Dyfrig A Hughes
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-05       Impact factor: 6.237

Review 2.  Costs and cost-effectiveness of malaria control interventions--a systematic review.

Authors:  Michael T White; Lesong Conteh; Richard Cibulskis; Azra C Ghani
Journal:  Malar J       Date:  2011-11-03       Impact factor: 2.979

Review 3.  Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review.

Authors:  Amani Thomas Mori; Bjarne Robberstad
Journal:  BMC Med Inform Decis Mak       Date:  2012-09-27       Impact factor: 2.796

4.  Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness.

Authors:  James Buchanan; Borislava Mihaylova; Alastair Gray; Nicholas White
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

5.  Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children.

Authors:  Amanda Ross; Nicolas Maire; Elisa Sicuri; Thomas Smith; Lesong Conteh
Journal:  PLoS One       Date:  2011-04-07       Impact factor: 3.240

6.  Quantifying behavioural interactions between humans and mosquitoes: evaluating the protective efficacy of insecticidal nets against malaria transmission in rural Tanzania.

Authors:  Gerry F Killeen; Japhet Kihonda; Edith Lyimo; Fred R Oketch; Maya E Kotas; Evan Mathenge; Joanna A Schellenberg; Christian Lengeler; Thomas A Smith; Chris J Drakeley
Journal:  BMC Infect Dis       Date:  2006-11-10       Impact factor: 3.090

7.  Simulation of the cost-effectiveness of malaria vaccines.

Authors:  Fabrizio Tediosi; Nicolas Maire; Melissa Penny; Alain Studer; Thomas A Smith
Journal:  Malar J       Date:  2009-06-08       Impact factor: 2.979

8.  Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

Authors:  Mark E Polhemus; Shon A Remich; Bernhards R Ogutu; John N Waitumbi; Lucas Otieno; Stella Apollo; James F Cummings; Kent E Kester; Christian F Ockenhouse; Ann Stewart; Opokua Ofori-Anyinam; Isabelle Ramboer; Conor P Cahill; Marc Lievens; Marie-Claude Dubois; Marie-Ange Demoitie; Amanda Leach; Joe Cohen; W Ripley Ballou; D Gray Heppner
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

9.  What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines.

Authors:  Melissa A Penny; Nicolas Maire; Alain Studer; Allan Schapira; Thomas A Smith
Journal:  PLoS One       Date:  2008-09-11       Impact factor: 3.240

10.  The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.

Authors:  Melissa A Penny; Katya Galactionova; Michael Tarantino; Marcel Tanner; Thomas A Smith
Journal:  BMC Med       Date:  2015-07-29       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.